Although treating atherosclerosis with theÂ
drug decitabine is not a viable option clinically, Jo's team was able to find several genes that are silenced by disturbed blood flow and that need DNA methylation to stay shut off.
Glioblastoma cells do not naturally produce NY - ESO - 1, so
the drug decitabine is given prior to injecting the NY - ESO - 1 targeting T cells in order to cause the tumor cells to express the NY - ESO - 1 target.
Not exact matches
New findings published in the Proceedings of the National Academy of Sciences showed in lab studies that supplementing an epigenetic cancer
drug called
decitabine with vitamin C enhanced the
drug's ability to impede cancer cell growth and trigger cellular self - destruction in cancer cell lines.
Decitabine is approved by the U.S. Food and
Drug Administration to treat myelodysplastic syndromes and leukemia, and for use in clinical trials for several types of solid - tumour cancers including colorectal.
A study led by UCLA's Drs. Robert Prins and Linda Liau, both UCLA Jonsson Comprehensive Cancer Center members, looked at the impact of a combined treatment using a chemotherapy
drug called
decitabine and genetically modified immune cells or T cell immunotherapy.
The
drugs, azacitidine (AZA) and
decitabine (DAC), are epigenetic - targeted
drugs and work to correct cancer - causing alterations that modify DNA.